trial

Bifeprunox in the Treatment of Schizophrenia

NCTId NCT00193687
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 986 (actual)
Sponsored by Solvay Pharmaceuticals
Primary completion 2008-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
986 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2005-09
Primary completion
2008-01
Eligibility
ALL · 18 Years · 75 Years

Interventions & indications

Drugs
Bifeprunox

Sponsors

Solvay PharmaceuticalsLead Sponsor

Investigators

1
Global Clinical Director SolvayStudy Director

Sites

0 total

Linked catalysts

1
Bifeprunox in the Treatment of Schizophrenia — primary completion2008-01

Facts & assertions

4 sourced
Enrollment
986
Phase
PHASE3
Primary Completion Date
2008-01
Status
COMPLETED
relationships
The graph out of here
drug
Bifeprunox
drug
lead_sponsor
Solvay Pharmaceuticals
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Global Clinical Director Solvay
person